Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period.
about
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining IssuesControversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinomaBiomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaRecent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRIConsiderations regarding current diagnosis and prognosis of hepatocellular carcinomaRole of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors.Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma.Cancer stem cells in primary liver cancers: pathological concepts and imaging findings.Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine AminotransferaseUse of Myometrium as an Internal Reference for Endometrial and Cervical Cancer on Multiphase Contrast-Enhanced MRI.Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization.Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinomaHepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment.Dynamic changes in ultrasound characteristics of nodules in cirrhotic liver and their implications in surveillance for malignancy.Trends in early-stage hepatocellular carcinoma, California 1988-2010.Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.Histone-modifying genes as biomarkers in hepatocellular carcinoma.Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients.Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma.Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma.Rate of seeding with biopsies and ablations of hepatocellular carcinoma: A retrospective cohort study.Assessing patients with hepatocellular carcinoma meeting the Milan criteria: Is liver 3 tesla MR with gadoxetic acid necessary in addition to liver CT?Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma
P2860
Q26752478-14A05CE6-6EEE-4FD3-96F0-662883214A78Q26770020-72B6D37F-7A2E-47F9-B46C-75DAB28F433BQ26772324-629604C1-6021-4D51-B29E-C38421D37D34Q27003291-2E00CA34-D424-4EB0-BCAA-A3D4876A4853Q28075361-C364DB6B-74AC-4C60-B3B4-D182B9EDFF9FQ28082223-7310E8FB-FA77-4F31-BA00-C99DE6B42095Q34182112-E2F020D3-8B07-42DA-A002-99568D3D5884Q34207863-9953DD93-E877-46E1-914D-10E1041CF59AQ34975197-EC9D201C-493B-4DF9-9FA0-821B7251B65CQ35940554-BCC6B17E-BF03-4DBD-9C16-F4EF0AB28E0AQ36052952-7CC7DEE3-A30B-41D0-99BE-62AEEC9BA849Q36057509-540746B1-B046-4615-9434-6F4621116A2DQ36682647-A93A6FE1-2D49-45C1-A608-6A77479E1C0FQ36962089-40BCCD47-43ED-4A15-8CCD-F3949CFCAD73Q37068236-BD3A13DE-28AA-4F5B-A59A-FCA33A44F31EQ37343300-32A78D5E-7FA5-4ED4-83A9-E6D924ACD218Q37725272-A7345BF2-2C3B-4208-8F1B-474BE54082E6Q38670649-9BD61F4B-A54A-495D-84D3-A6E54BF962EEQ39699286-8CC1E47C-6B57-4033-B09B-E78A5E517609Q40217122-D2398522-DBF8-47EA-8041-A267513DB8FBQ40692653-37ABDB92-5A08-4F49-A7B4-9239A41E3480Q41135024-CB77FCF2-EBF0-455F-9ED3-81EF1DBE4E66Q44088955-5ABB1FC3-788D-4187-A2B2-BB175189D40BQ44199365-937B6DC5-37E0-40F5-AA49-BFB10AFBD64FQ47101417-90747890-3002-4C73-B931-3954C330E920Q52733595-718EF307-0DD5-4A2B-9A52-106461229003Q53092360-E8DC410B-E9AE-4629-ABB0-D6E678DF1C2DQ58707841-D24BA63F-30A9-4A89-A5A2-167EEC0884A1
P2860
Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Changes of guidelines diagnosi ...... ring the last ten-year period.
@en
type
label
Changes of guidelines diagnosi ...... ring the last ten-year period.
@en
prefLabel
Changes of guidelines diagnosi ...... ring the last ten-year period.
@en
P2860
P1476
Changes of guidelines diagnosi ...... ring the last ten-year period.
@en
P2093
Do Seon Song
Si Hyun Bae
P2860
P304
P356
10.3350/CMH.2012.18.3.258
P5008
P577
2012-09-01T00:00:00Z
2012-09-25T00:00:00Z